Holen Sie sich die Stockscreener-App
33.41
3.37%
-1.165
Sionna Therapeutics Inc Aktie (SION) Neueste Nachrichten
TD Asset Management Inc Grows Position in Sionna Therapeutics, Inc. $SION - MarketBeat
Reassessing Sionna Therapeutics (SION) Valuation After Recent Share Price Pullback And CF Pipeline Progress - simplywall.st
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
SION: NBD1 stabilization could transform CF care, with dual and add-on therapies advancing in clinical trials - TradingView
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownShould You Sell? - MarketBeat
Sionna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Guggenheim raises Sionna Therapeutics stock price target to $50 By Investing.com - Investing.com Canada
Sionna Therapeutics Inc maintains strong cash position with about $310.3 million in cash and cash equivalents, expected to fund operations into 2028 - marketscreener.com
Sionna Therapeutics Inc Maintains Strong Cash Position With About $310.3 Million In Cash And Cash Equivalents, Expected To Fund Operations Into 2028 - TradingView
Form S-3ASR Sionna Therapeutics, - StreetInsider
Sionna Therapeutics Q4 Net Loss Narrows - marketscreener.com
Sionna Therapeutics (SION) outlines NBD1-focused cystic fibrosis drug pipeline - Stock Titan
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Sionna Therapeutics 10-K: $0 Revenue, $(1.88) EPS - TradingView
Sionna Therapeutics (Nasdaq: SION) posts 2025 loss, ends year with $310.3M cash - Stock Titan
Sionna backs cystic fibrosis trials with $310M cash runway to 2028 - Stock Titan
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum - Yahoo Finance
Sionna Therapeutics, Inc. (SION) Stock Analysis: A Promising 24% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Sionna Therapeutics (NASDAQ:SION) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
JPMorgan Chase & Co. Cuts Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Citizens Initiates Coverage of Sionna Therapeutics (SION) with Market Outperform Recommendation - Nasdaq
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Market Recap: Is FIVE in a consolidation phase2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Cystic fibrosis drug developer Sionna heads to key March investor events - Stock Titan
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences - The Manila Times
Sionna Therapeutics, Inc. (SION) Stock Analysis: A High-Stakes Bet on Biotech Innovation with 20.13% Upside Potential - DirectorsTalk Interviews
Is Sionna Therapeutics Inc. still a buy after recent gainsJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - mfd.ru
Fed Meeting: Will Sionna Therapeutics Inc outperform tech stocks2025 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit - Yahoo Finance
2026 Milestones in Focus as Sionna Therapeutics Pursues NBD1 Stabilization for CFTR - AD HOC NEWS
Sionna Therapeutics, Inc. (SION) Investor Outlook: Analyzing a 19% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
Can Sionna Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Breakouts & Technical Confirmation Alerts - mfd.ru
What’s the MACD signal for Sionna Therapeutics Inc.July 2025 Outlook & Risk Adjusted Buy/Sell Alerts - mfd.ru
Volume Recap: Should you avoid Sionna Therapeutics Inc stock right nowEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Peter Thompson Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling - Defense World
Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling - MarketBeat
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com Australia
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m - Investing.com Canada
Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 29,063 Shares - MarketBeat
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - markets.businessinsider.com
Sionna Therapeutics (NASDAQ:SION) Director Sells $1,295,628.54 in Stock - MarketBeat
Support Test: Whats the outlook for Sionna Therapeutics Incs sectorTrade Risk Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TPG GP A, LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. (SION) Stock Analysis: Biotech’s Promising Prospects with 5.7% Upside Potential - DirectorsTalk Interviews
Sionna Therapeutics (SION) 10% owners sell $10 million in stock By Investing.com - Investing.com South Africa
Major Stake Unloaded in Sionna Therapeutics Sparks Fresh Market Buzz - TipRanks
Tpg Gp A, Llc Sells 250,000 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (SION) 10% owners sell $10 million in stock - Investing.com
4.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):